Measles is becoming an important public health problem and it is important to recognize and understand the origins of this problem and how it can affect the population of our country. At the same time, it is critical to have updated and scientifically accurate information on the clinical presentations, risk factors and countermeasures. Today, we will discuss this topic with experts in field. 

Watch this episode: https://youtu.be/oQDaa8J9v5w

Topics:

 • Define measles as an important public health threat  • Explain the origin of the epidemic  • Accurate information on countermeasures and strategies to tackle this outbreak.

Guests: 

- Hana Mohammed El Sahly, M.D.  Professor, Kyle and Josephine Morrow Chair, Department of Medicine, Molecular Virology and Microbiology; Vaccine and Treatment Evaluation Unit (VTEU) Baylor College of Medicine Houston, TX US.

- Natasha B. Halasa M.D., M.P.H. Craig Weaver Professor of Pediatrics, Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University, Nashville Tennessee

This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at https://asm.org/aac. 

If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit https://asm.org/joinasm to sign up.

Visit https://asm.org/aac to browse issues and/or submit a manuscript.

Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates. 

Subscribe to the podcast at https://asm.org/eic 

With Alex’s departure to new pastures, which include things like being the incoming President of ASM, we now have a new JCM Editor-in-Chief, Dr. Romney Humphries! Dr. Humphries is currently Director of the Division of Laboratory Medicine and Medical Director of the Microbiology Laboratory at Vanderbilt University, as well as a Professor of Pathology, Microbiology and Immunology. She is an absolute powerhouse in the AST world as we all know, and as of this month, is the new Editor in Chief of JCM. In this episode, we find out Dr. Humphries’s vision and new ideas for the Journal and where she’d like to see JCM go over the next few years.

Watch this episode: https://youtu.be/xkyUb6zE9X4

• Romney Humphries, Ph.D., D(ABMM), M(ASCP)

This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript.

Follow JCM on Twitter/𝕏 via @JClinMicro

A common description of antibiotic action aims to classify them between “bactericidal” or “bacteriostatic”. Although these phenomena have robust in vitro foundations, the clinical translation of these concepts is sometimes difficult to ascertain. This controversial topic has important conceptual ramifications to treat severe infections. Today, we will discuss this topic with an expert in field. 

Watch the video version here: https://youtu.be/3z4BItBrzbk

• The definitions of “cidal” vs “static” antibiotics
• The clinical applicability of the above terms in terms of antibiotic choice and syndromatic approaches
• antibiotic choices and the controversy between bactericidal and bacteriostatic antibiotics. 

• Brad Spellberg, MD.  Chief Medical Officer at the Los Angeles General Medical Center 

• ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026
• Watch this session on YouTube

This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal. 

Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Oversight and guidance for performing antibiotic susceptibility testing can be bewildering. There is an alphabet soup of agencies and bodies involved: FDA, CLSI, and USCAST, to name a few here in the US. How does the Food and Drug Administration, which has regulatory authority over AST, work with a nimble group like the Clinical Laboratory Standards Institute?

• Romney Humphries, Ph.D., D(ABMM), M(ASCP)
• Patricia Simner, Ph.D., D(ABMM)

• Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance
• Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals.
• Attend ASM Microbe

This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript.

Follow JCM on Twitter/𝕏 via @JClinMicro

In the last decade, there have been major changes in the approach of the treatment of pneumonia, in particular, with the availability of new diagnostic tools. Additionally, new drugs have been approved for the treatment of pneumonia. We discuss the approach to the management of pneumonia with a person who has spent most of his professional career working on this topic.

• Definitions and nomenclature of pneumonia and evolution of these terms
• Changes in the diagnosis of pneumonia
• Ttherapeutic changes and future approaches for the treatment of pneumonia.

• Daniel M Musher, M.D.

• ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026

This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal. 

Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Picture this, you wake up one morning with nausea, body aches, abdominal pain, and despite sleeping all night, you are exhausted. You then find yourself running to the restroom with watery and somewhat explosive diarrhea. You think to yourself – what could this be? Well, if the year was 2023, in the summer and you happen to live in Texas, chances were somewhat high that you had probably had cyclosporiasis.  And today, we are going to talk about this particular parasite and focus in on what our options are for detecting it given that it is not routinely picked up on O&P exams. And while there are molecular panels out there that include Cyclospora as a target, as our speakers will share, there is an easier and cheaper approach we can consider to quickly ID this pathogen.

• Dr. Angela Ma. Public Health Ontario and Assistant Professor at the University of Toronto
• Dr. Marc Couturier. Drector of the clinical microbiology lab at NorDx lab at MaineHealth in Scarborough, Maine

• Shedding new light on Cyclospora: how the use of ultraviolet fluorescence microscopy can improve diagnosis of cyclosporiasis
• Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals.
• Attend ASM Microbe

This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript.

Follow JCM on Twitter/𝕏 via @JClinMicro

The past year in Clinical Microbiology, as seen through the lens of the Journal of Clinical Microbiology. Four JCM editors have each selected a paper they consider to be among the “best” we published in 2024. Of course there are no objective criteria for what makes a paper the “best.” So, by “best,” we mean “a paper that I find exciting.”

View this episode: https://www.youtube.com/watch?v=fK9ZqZUrDiY

• Patricia Simner, Ph.D., D(ABMM), Johns Hopkins University School of Medicine
• Romney Humphries, Ph.D., D(ABMM), M(ASCP), Vanderbilt University Medical Center

• Wood RC, Luabeya AK, Dragovich RB, Olson AM, Lochner KA, Weigel KM, Codsi R, Mulenga H, de Vos M, Kohli M, Penn-Nicholson A, Hatherill M, Cangelosi GA. 2024. Diagnostic accuracy of tongue swab testing on two automated tuberculosis diagnostic platforms, Cepheid Xpert MTB/RIF Ultra and Molbio Truenat MTB Ultima. J Clin Microbiol 62:e00019-24.
• Rodino KG, Luethy PM, Abbott AN, Bender JM, Eberly AR, Gitman M, Leber A, Dien Bard J, . 2024. Defining the value of medical microbiology consultation. J Clin Microbiol 62:e00359-24.
• Giske CG, Bressan M, Fiechter F, Hinic V, Mancini S, Nolte O, Egli A. 2024. GPT-4-based AI agents—the new expert system for detection of antimicrobial resistance mechanisms?. J Clin Microbiol 62:e00689-24.
• Bloomfield M, van der Werff K, Todd S, Bocacao M, Reed H, Balm M, Blackmore T. 2024. An exception-reporting approach for wound swab culture: effect on post-report antibiotic initiation. J Clin Microbiol 62:e00342-24.
• Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals.
• Attend ASM Microbe

This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript.

Follow JCM on Twitter/𝕏 via @JClinMicro

2024 was a very active year on research in antimicrobial resistance, highlighted by an impactful and high level political declaration to combat antimicrobial resistance by the United Nations. In this episode, trainees from NIH-funded training program (T32) on antimicrobial resistance will help me discuss the most relevant research on the field in the year 2024. Welcome to editors in conversation!

• The best papers of 2024 in gram-positive, gram-negative, mycobacterial and parasite resistance

• Nathalie Chen: University of Pittsburgh, Pittsburgh, PA
• Alex Kang: Houston Methodist Research Institute, Houston, TX
• Nathan Rabbe: University of Pittsburgh, Pittsburgh, PA
• Taylor Blackburn: Emory University, Atlanta, GA
• Jacon McPherson: University of Houston, Houston, TX.
• Harrison Lee, MD: Associate Chief of Epidemiology and Microbial Genomics, Professor of Medicine and Epidemiology, Director, Center for Genomic Epidemiology, Director, T32 AMR, U of Pittsburgh
• William Shafer, PhD: Professor, Department of Microbiology and Immunology, Emory University School of Medicine, Co-Director, Emory Antibiotic Resistance Center. Director T32 AMR, Emory University

This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal. 

Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Looking for a dynamic and rewarding career? Learn what it means to be a Clinical Microbiology Laboratory Director and the necessary steps to get there. It’s a diverse job encompassing infectious diseases diagnostic testing, patient care, teaching, and research. This episode is geared for those who are interested in pursuing (or already have) a Ph.D. or M.D.

• Alexandra Bryson, Ph.D.
• Andrea Prinzi, Ph.D

• Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals.

This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript.

Follow JCM on Twitter/𝕏 via @JClinMicro

Lack of access to antibiotics including those with enhanced activity against multidrug-resistant organisms is a major barrier to combat antimicrobial resistance, particularly in the developing world. Furthermore, discovering and making available new antimicrobial agents against the most pressing antibiotic-resitant organisms is a challenge due to multiple barriers. The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come. We discuss the important role that GARDP is playing in the worldwide fight against antimicrobial resistance.

• GARDP function and role in the AMR field
• The strategies that GARDP is implementing to make new antibiotics available to all
• The future of antimicrobial research and development and the role of GARDP in this process.

• Jennifer Cohn MD MPH, Director, Global Access Global Antibiotic R&D Partnership (GARDP)
• Susana Ribeiro, MPH, Regional Head Latin America Global Antibiotic R&D Partnership (GARDP)

This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal. 

Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.